Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Chemours Analyst Ratings and Price Targets | NYSE:CC | Benzinga
The Chemours Co has a consensus price target of $25.42 based on the ratings of 13 analysts. The high is $37 issued by B of A Securities on June 22, 2023. The low is $18 issued by JP Morgan on August 6, 2024. The 3 most-recent analyst ratings were released by Barclays, BMO Capital, and Truist Securities on February 24, 2025, February 19, 2025, and January 28, 2025, respectively. With an average price target of $24.33 between Barclays, BMO Capital, and Truist Securities, there's an implied 68.46% upside for The Chemours Co from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Barclays
BMO Capital
Truist Securities
Morgan Stanley
Mizuho
1calculated from analyst ratings
Analyst Ratings for Chemours
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 02/24/2025 | Buy Now | 31.53% | Barclays | Michael Leithead55% | $23 → $19 | Maintains | Equal-Weight | Get Alert |
| 02/19/2025 | Buy Now | 86.92% | BMO Capital | John McNulty60% | $34 → $27 | Maintains | Outperform | Get Alert |
| 01/28/2025 | Buy Now | 86.92% | Truist Securities | Peter Osterland17% | → $27 | Initiates | → Buy | Get Alert |
| 01/13/2025 | Buy Now | 52.3% | Morgan Stanley | Vincent Andrews78% | $25 → $22 | Maintains | Equal-Weight | Get Alert |
| 01/07/2025 | Buy Now | 45.38% | Mizuho | John Roberts75% | $22 → $21 | Maintains | Neutral | Get Alert |
| 01/07/2025 | Buy Now | 45.38% | Goldman Sachs | Duffy Fischer59% | $24 → $21 | Maintains | Neutral | Get Alert |
| 12/12/2024 | Buy Now | 73.07% | RBC Capital | Arun Viswanathan53% | $25 → $25 | Reiterates | Outperform → Outperform | Get Alert |
| 11/06/2024 | Buy Now | 73.07% | RBC Capital | Arun Viswanathan53% | $28 → $25 | Maintains | Outperform | Get Alert |
| 11/05/2024 | Buy Now | 59.22% | Barclays | Michael Leithead55% | $21 → $23 | Maintains | Equal-Weight | Get Alert |
| 11/05/2024 | Buy Now | 73.07% | Morgan Stanley | Vincent Andrews78% | $30 → $25 | Maintains | Equal-Weight | Get Alert |
| 10/11/2024 | Buy Now | 93.84% | RBC Capital | Arun Viswanathan53% | $35 → $28 | Maintains | Outperform | Get Alert |
| 10/07/2024 | Buy Now | 121.53% | BMO Capital | John McNulty60% | $30 → $32 | Maintains | Outperform | Get Alert |
| 09/25/2024 | Buy Now | 45.38% | Barclays | Michael Leithead55% | $22 → $21 | Maintains | Equal-Weight | Get Alert |
| 09/03/2024 | Buy Now | 59.22% | Goldman Sachs | Duffy Fischer59% | $29 → $23 | Maintains | Neutral | Get Alert |
| 08/06/2024 | Buy Now | 24.61% | JP Morgan | Jeffrey Zekauskas67% | $25 → $18 | Maintains | Neutral | Get Alert |
| 08/06/2024 | Buy Now | 93.84% | UBS | Joshua Spector54% | $30 → $28 | Maintains | Buy | Get Alert |
| 08/06/2024 | Buy Now | 107.68% | BMO Capital | John McNulty60% | $35 → $30 | Maintains | Outperform | Get Alert |
| 08/06/2024 | Buy Now | 52.3% | Barclays | Michael Leithead55% | $30 → $22 | Maintains | Equal-Weight | Get Alert |
| 07/09/2024 | Buy Now | 107.68% | UBS | Joshua Spector54% | $28 → $30 | Upgrade | Neutral → Buy | Get Alert |
| 06/07/2024 | Buy Now | 73.07% | Mizuho | John Roberts75% | → $25 | Initiates | → Neutral | Get Alert |
| 04/09/2024 | Buy Now | 135.38% | BMO Capital | John McNulty60% | $19 → $34 | Upgrade | Market Perform → Outperform | Get Alert |
| 04/02/2024 | Buy Now | 93.84% | UBS | Joshua Spector54% | $21 → $28 | Maintains | Neutral | Get Alert |
| 04/02/2024 | Buy Now | 107.68% | Barclays | Michael Leithead55% | $32 → $30 | Maintains | Equal-Weight | Get Alert |
| 03/05/2024 | Buy Now | 45.38% | UBS | Joshua Spector54% | $37 → $21 | Downgrade | Buy → Neutral | Get Alert |
| 03/01/2024 | Buy Now | 31.53% | BMO Capital | John McNulty60% | $45 → $19 | Downgrade | Outperform → Underperform | Get Alert |
| 02/29/2024 | Buy Now | 31.53% | BMO Capital | John McNulty60% | $45 → $19 | Downgrade | Outperform → Underperform | Get Alert |
| 12/01/2023 | Buy Now | 176.91% | RBC Capital | Arun Viswanathan53% | $28 → $40 | Upgrade | Sector Perform → Outperform | Get Alert |
| 11/07/2023 | Buy Now | 79.99% | JP Morgan | Jeffrey Zekauskas67% | $38 → $26 | Maintains | Neutral | Get Alert |
| 10/31/2023 | Buy Now | 107.68% | Goldman Sachs | Duffy Fischer59% | $35 → $30 | Maintains | Neutral | Get Alert |
| 10/30/2023 | Buy Now | 93.84% | RBC Capital | Arun Viswanathan53% | $30 → $28 | Maintains | Sector Perform | Get Alert |
| 10/30/2023 | Buy Now | 169.99% | BMO Capital | John McNulty60% | $45 → $39 | Maintains | Outperform | Get Alert |
| 10/30/2023 | Buy Now | 93.84% | Morgan Stanley | Vincent Andrews78% | $33 → $28 | Maintains | Equal-Weight | Get Alert |
| 10/30/2023 | Buy Now | 93.84% | Barclays | Michael Leithead55% | $31 → $28 | Maintains | Equal-Weight | Get Alert |
| 10/04/2023 | Buy Now | 114.61% | Barclays | Michael Leithead55% | $40 → $31 | Maintains | Equal-Weight | Get Alert |
| 08/02/2023 | Buy Now | 266.91% | BMO Capital | John McNulty60% | $64 → $53 | Maintains | Outperform | Get Alert |
| 08/01/2023 | Buy Now | 128.45% | Morgan Stanley | Vincent Andrews78% | $33 → $33 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 07/31/2023 | Buy Now | 176.91% | RBC Capital | Arun Viswanathan53% | $37 → $40 | Maintains | Sector Perform | Get Alert |
| 07/19/2023 | Buy Now | 128.45% | Morgan Stanley | Vincent Andrews78% | $33 → $33 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 07/11/2023 | Buy Now | 176.91% | Barclays | Michael Leithead55% | $38 → $40 | Maintains | Equal-Weight | Get Alert |
| 06/22/2023 | Buy Now | 156.14% | B of A Securities | Matthew DeYoe43% | $41 → $37 | Downgrade | Buy → Neutral | Get Alert |
| 06/13/2023 | Buy Now | 197.68% | UBS | Joshua Spector54% | $41 → $43 | Maintains | Buy | Get Alert |
| 06/09/2023 | Buy Now | 156.14% | RBC Capital | Arun Viswanathan53% | $36 → $37 | Maintains | Sector Perform | Get Alert |
| 06/05/2023 | Buy Now | 343.06% | BMO Capital | John McNulty60% | $54 → $64 | Maintains | Outperform | Get Alert |
| 05/31/2023 | Buy Now | 107.68% | JP Morgan | Jeffrey Zekauskas67% | $35 → $30 | Maintains | Neutral | Get Alert |
| 05/01/2023 | Buy Now | 149.22% | RBC Capital | Arun Viswanathan53% | $35 → $36 | Maintains | Sector Perform | Get Alert |
| 05/01/2023 | Buy Now | 273.83% | BMO Capital | John McNulty60% | $52 → $54 | Maintains | Outperform | Get Alert |
| 04/28/2023 | Buy Now | 73.07% | Credit Suisse | John Roberts75% | $27 → $25 | Maintains | Underperform | Get Alert |
| 02/14/2023 | Buy Now | 163.07% | Goldman Sachs | Duffy Fischer59% | $34 → $38 | Maintains | Neutral | Get Alert |
| 02/13/2023 | Buy Now | 142.3% | Citigroup | PJ Juvekar68% | $33 → $35 | Maintains | Neutral | Get Alert |
| 02/13/2023 | Buy Now | 149.22% | RBC Capital | Arun Viswanathan53% | $33 → $36 | Maintains | Sector Perform | Get Alert |
| 02/10/2023 | Buy Now | 86.92% | Credit Suisse | John Roberts75% | $24 → $27 | Maintains | Underperform | Get Alert |
| 01/24/2023 | Buy Now | 197.68% | UBS | Joshua Spector54% | $31 → $43 | Upgrade | Neutral → Buy | Get Alert |
| 01/11/2023 | Buy Now | 114.61% | UBS | Joshua Spector54% | $29 → $31 | Maintains | Neutral | Get Alert |
| 01/11/2023 | Buy Now | 176.91% | B of A Securities | Matthew DeYoe43% | $37 → $40 | Upgrade | Neutral → Buy | Get Alert |
| 01/10/2023 | Buy Now | 128.45% | RBC Capital | Arun Viswanathan53% | $35 → $33 | Downgrade | Outperform → Sector Perform | Get Alert |
| 12/15/2022 | Buy Now | 128.45% | Citigroup | PJ Juvekar68% | $30 → $33 | Maintains | Neutral | Get Alert |
| 11/01/2022 | Buy Now | 66.15% | Credit Suisse | John Roberts75% | → $24 | Initiates | → Underperform | Get Alert |
| 10/27/2022 | Buy Now | 183.84% | BMO Capital | John McNulty60% | $46 → $41 | Maintains | Outperform | Get Alert |
| 10/25/2022 | Buy Now | 128.45% | Morgan Stanley | Vincent Andrews78% | $41 → $33 | Maintains | Equal-Weight | Get Alert |
| 10/13/2022 | Buy Now | 107.68% | Goldman Sachs | Duffy Fischer59% | → $30 | Initiates | → Neutral | Get Alert |
| 10/05/2022 | Buy Now | — | Argus Research | David Coleman62% | — | Downgrade | Buy → Hold | Get Alert |
| 09/27/2022 | Buy Now | 107.68% | Barclays | Michael Leithead55% | $46 → $30 | Maintains | Equal-Weight | Get Alert |
| 09/23/2022 | Buy Now | 218.45% | BMO Capital | John McNulty60% | $55 → $46 | Maintains | Outperform | Get Alert |
| 09/22/2022 | Buy Now | 142.3% | RBC Capital | Arun Viswanathan53% | $48 → $35 | Maintains | Outperform | Get Alert |
| 08/01/2022 | Buy Now | 232.29% | RBC Capital | Arun Viswanathan53% | $44 → $48 | Maintains | Outperform | Get Alert |
| 07/29/2022 | Buy Now | 156.14% | UBS | Joshua Spector54% | $35 → $37 | Maintains | Neutral | Get Alert |
| 06/14/2022 | Buy Now | 204.6% | B of A Securities | Matthew DeYoe43% | $48 → $44 | Downgrade | Buy → Neutral | Get Alert |
| 05/09/2022 | Buy Now | 183.84% | Morgan Stanley | Vincent Andrews78% | $35 → $41 | Maintains | Equal-Weight | Get Alert |
| 05/09/2022 | Buy Now | 218.45% | Barclays | Michael Leithead55% | $37 → $46 | Maintains | Equal-Weight | Get Alert |
| 05/04/2022 | Buy Now | 232.29% | RBC Capital | Arun Viswanathan53% | $42 → $48 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Chemours (CC) stock?
The latest price target for Chemours (NYSE:CC) was reported by Barclays on February 24, 2025. The analyst firm set a price target for $19.00 expecting CC to rise to within 12 months (a possible 31.53% upside). 23 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Chemours (CC)?
The latest analyst rating for Chemours (NYSE:CC) was provided by Barclays, and Chemours maintained their equal-weight rating.
When was the last upgrade for Chemours (CC)?
The last upgrade for The Chemours Co happened on July 9, 2024 when UBS raised their price target to $30. UBS previously had a neutral for The Chemours Co.
When was the last downgrade for Chemours (CC)?
The last downgrade for The Chemours Co happened on March 5, 2024 when UBS changed their price target from $37 to $21 for The Chemours Co.
When is the next analyst rating going to be posted or updated for Chemours (CC)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Chemours, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Chemours was filed on February 24, 2025 so you should expect the next rating to be made available sometime around February 24, 2026.
Is the Analyst Rating Chemours (CC) correct?
While ratings are subjective and will change, the latest Chemours (CC) rating was a maintained with a price target of $23.00 to $19.00. The current price Chemours (CC) is trading at is $14.45, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.